Research Progress of Nanodelivery Systems for Pancreatic Cancer

Pancreatic cancer is characterised by its aggressive nature and poor prognosis, mainly due to its complex biology. The tumour microenvironment plays an important role and is composed of different cellular components that enable tumour growth and metastasis. Cellular heterogeneity further complicates treatment, as different cell populations within the tumour behave and respond differently to treatment. Against this background, nano-delivery systems such as liposomes, micelles and exosomes have emerged as promising strategies to improve drug delivery and efficacy. These systems can improve bioavailability and targeting and overcome some of the limitations of conventional therapies. However, challenges remain in optimising drug delivery mechanisms, ensuring biocompatibility and managing the complexity of the tumour microenvironment. Future research should focus on overcoming these obstacles in order to realise the full potential of nanotransduction systems in the treatment of pancreatic cancer.